Androgen Receptor is a Backdoor Inhibitor of Wildtype and Mutant Estrogen Receptors in Refractory Hormone Receptor-Positive Breast Cancers

ABSTRACT: Ligand-activated AR inhibits wildtype and mutant-refractory ER activity in PDXs by reprogramming the ER and FOXA1 cistrome and rendering tumor-growth inhibition. These findings suggest that ligand-activated AR may function as a backdoor inhibitor of ER and that AR agonists may offer a safe and effective treatment for ER-positive breast cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE128018 | GEO | 2019/09/19

REPOSITORIES: GEO